Ionis Pharmaceuticals, Inc.

Organisation

2855 Gazelle Court, Carlsbad, CA, United States, 92010

Headquarters

1402

Employees

Health Technology

Industry

Brett Monia

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Price

Target

Ionis Pharmaceuticals, Inc. (IONS) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Ionis Pharmaceuticals, Inc. (IONS) share price will touch around $96.81 in next 12-months.

Currently 30 wall-street analysts regularly analyze the financials of Ionis Pharmaceuticals, Inc. on a frequent basis to provide recommendations along with target share price. 30 analysts offering 12-month price forecasts for Ionis Pharmaceuticals, Inc. (IONS) have a share price target of $96.81. This median of share price forecast represents a 29.42% upside from the latest price of $74.8 as on 05.04.26.

Ionis Pharmaceuticals, Inc. (IONS) Share Price Forecast

Home

US Stocks

Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. Stock Forecast

Ionis Pharmaceuticals, Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Ionis Pharmaceuticals, Inc. (IONS): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Ionis Pharmaceuticals, Inc.'s share price and its median forecast price. As on 05.04.26, the difference is -22.39%

Ionis Pharmaceuticals, Inc. Forecast and Target Price

Ionis Pharmaceuticals, Inc. (IONS) Share Price Forecast

Ionis Pharmaceuticals, Inc. (IONS) Price vs Consensus Price Target

Ionis Pharmaceuticals, Inc. (IONS) Share Price Forecast v/s Share Price Today

Ionis Pharmaceuticals, Inc. (IONS): Difference between Current Price & Median Forecasted Price

Ionis Pharmaceuticals, Inc. (IONS) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price